Market Cap: $20.38B
II
Insmed Incorporated
INSM
NASDAQ (NASDAQ Global Select)USD
Market Cap: $20.38B
In a notable development, Insmed Incorporated (Ticker: INSM) appoints Samuele Butera as the new Senior Vice President for Global Respiratory, strong-arming its focus on respiratory therapies amid shif…
Insmed (Ticker: INSM) announces the appointment of Samuele Butera as the Senior Vice President and General Manager of its Global Respiratory division, bolstering its leadership team at a critical junc…
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…
Insmed Inc. (Ticker: INSM) is experiencing significant excitement around its newly launched medication, brensocatib, due to encouraging feedback from physicians. The early responses suggest a broad pr…
Insmed Incorporated (Ticker: INSM) continues to solidify its presence in the biopharmaceuticals sector through strategic hiring and promising clinical trial results. Recently, the company announced th…
Insmed (Ticker: INSM) is navigating strategic financial adjustments to bolster its operations. Recently, the company has filed an automatic shelf registration, aiming to issue common stock and debt se…
Insmed Incorporated demonstrates a strong commitment to advancing treatment for pulmonary diseases, as evidenced by its participation in the upcoming American Thoracic Society International Conference…
Insmed Incorporated, known for its commitment to developing innovative therapies in the biotech sector, faces a significant setback as its Phase 2b clinical trial results on brensocatib for hidradenit…
Promising Advancements in Mycobacterium Avium Complex Treatment Insmed Incorporated is making significant strides in the treatment of Mycobacterium avium complex (MAC) lung infections, a condition kno…
Insmed's Commitment to Workforce Growth through Inducement Awards Insmed Incorporated, a global biopharmaceutical leader based in Bridgewater, New Jersey, recently takes a significant step in its grow…
Insmed's Commitment to Talent Acquisition and Employee Retention Insmed Incorporated, a prominent biopharmaceutical company based in Bridgewater, New Jersey, demonstrates its commitment to attracting…
Insmed Strengthens Workforce with Inducement Awards in Biopharmaceutical Sector On March 5, 2026, Insmed Incorporated, a leading biopharmaceutical company headquartered in Bridgewater, New Jersey, ann…
Analyst chorus flags strategic questions at Insmed Divergent analyst views highlight regulatory and clinical uncertainty Insmed is facing a split set of professional assessments as 16 analysts issue m…
Insmed times pre‑market Q4 disclosure to frame operational priorities Q4 filing frames commercial and development priorities Insmed releases its fourth‑quarter 2025 results on Feb. 19, 2026 at 07:00 a…
Insmed frames Q4 report as a strategic update on commercial traction and pipeline progress Insmed is issuing its fourth-quarter 2025 results in a timed release that serves primarily as a strategic upd…
Insmed times quarterly disclosure to outline commercial and pipeline progress Insmed issues its fourth-quarter 2025 results on Feb. 19, 2026 at 07:00 ET, delivering the routine mix of financial figure…
Management to outline pulmonary and inflammatory strategy at two March conferences Insmed Incorporated is presenting its clinical and commercial strategy at two major healthcare investor conferences i…
Insmed to present R&D strategy and pipeline at two March investor conferences Insmed Inc. says company management will present its clinical and research strategy at two industry conferences in March 2…
Insmed’s Promising Pipeline: Fueling Growth in Rare Lung Diseases Insmed's recent performance highlights the company's significant advancements in treating rare lung diseases, particularly with the co…
Insmed's Brinsupri Drives Significant Market Growth Insmed is currently experiencing a remarkable transformation in the biotech landscape, primarily fueled by the success of its lead product, Brinsupr…
Insmed's Strategic Focus on Innovative Respiratory Treatments Insmed Incorporated, a biopharmaceutical company dedicated to developing therapies for serious diseases, highlights its commitment to addr…
Insmed's Strategic Vision for Advancing Respiratory Therapies Insmed Incorporated, a biopharmaceutical company dedicated to innovative treatments for serious diseases, showcases a robust financial per…
Insmed’s Commitment to Innovative Therapies in Serious Diseases Insmed Incorporated, a biopharmaceutical company headquartered in Bridgewater, New Jersey, stands at the forefront of developing innovat…
### Insmed's Commitment to Innovative Therapies: A Focus on Patient-Centric Solutions Insmed Incorporated, a biopharmaceutical company headquartered in Bridgewater, New Jersey, is making significant s…
Insmed Discontinues Phase 2b Study of Brensocatib for Chronic Rhinosinusitis, Shifts Focus to New Therapy Insmed Incorporated, a biopharmaceutical company renowned for its innovative treatment approac…